NDAINTRAVENOUSPOWDERPriority Review
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XERAVA (eravacycline) is an intravenous fluorocycline antibiotic approved in 2018 for treating complicated intra-abdominal infections. It represents a tetracycline-class advancement with activity against multidrug-resistant gram-negative and gram-positive pathogens. The drug is currently in peak commercial lifecycle with 11.3 years of patent protection remaining.
$0.788MPart D
Peak11.3 years to LOEEarly-stage commercial maturation with limited Part D penetration suggests ongoing market expansion opportunities and sustained brand-building investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
Started May 2025
35 enrolled
Complicated Intra-abdominal Infections (cIAI)
Eravacycline Combination Therapy for MRAB
Started Jan 2024
20 enrolled
Pulmonary InfectionPneumonia, BacterialAcinetobacter Baumannii
Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women
Started Nov 2012
20 enrolled
Normal Drug Tolerance
Career Relevance
XERAVA roles are concentrated in specialty physician engagement across surgical and procedural specialties where complicated intra-abdominal infections are prevalent. Working on XERAVA offers experience building niche market penetration in a stable, patent-protected franchise with surgical center and hospital-focused commercial strategies.
Worked on XERAVA at RAPHAS? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.